CiMaas

Description

CiMaas develops cellular immunotherapies using expanded Natural Killer (NK) cells as advanced therapeutic products for cancer patients and related clinical applications.

Related

• Constructive BioConstructive Bio designs and manufactures new-to-nature proteins and enables scalable production of therapeutics and advanced materials…
• ORCA TherapeuticsORCA Therapeutics develops oncolytic virus immunotherapies for prostate cancer, producing lead therapeutic ORCA-010 for treatment-naive…
• ONK TherapeuticsONK Therapeutics develops off-the-shelf, optimally engineered natural killer (NK) cell therapies combining CAR and TRAIL variant constructs…
• Vivere OncotherapiesVivere Oncotherapies develops bioengineered cancer immunotherapies designed to help patients’ immune systems target cold tumors and support…
• OncoGenOncoGen conducts research and microproduction for cancer, allergies and regenerative medicine, developing gene‑cell therapies, anti‑cancer…
• Faron Pharmaceuticals Ltd.Faron Pharmaceuticals Ltd. develops immunotherapies that leverage patients' immune systems for cancer treatment, serving clinical…
• BioNTechBioNTech develops immunotherapies and mRNA vaccines for cancer, infectious diseases and other serious illnesses, serving patients through…
• HAL AllergyHAL Allergy develops, produces and distributes allergen immunotherapies and modified allergen extracts for therapeutic and diagnostic use,…
• Legend Biotech ($LEGN)Legend Biotech develops CAR-T cell therapies targeting blood cancers and solid tumors, advancing cellular research to expand treatment…
• brainjobrainjo develops digital tools and therapeutic candidates for brain health, building products for cognitive training and related…
• Iovance Biotherapeutics ($IOVA)Iovance Biotherapeutics develops and manufactures tumor-infiltrating lymphocyte (TIL) cell therapies for treating solid tumors, running…
• NKINKI conducts cancer research and provides patient care, developing fundamental, translational and clinical research, technologies and…